Search hospitals > Louisiana > New Orleans
Tulane University School of Medicine
Claim this profileNew Orleans, Louisiana 70112
Global Leader in Cancer
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Leukemia
Conducts research for Prostate Cancer
Conducts research for Fibrosis
284 reported clinical trials
38 medical researchers
Summary
Tulane University School of Medicine is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Human Immunodeficiency Virus Infection, Leukemia, Prostate Cancer, Fibrosis and other specialties. Tulane University School of Medicine is involved with conducting 284 clinical trials across 916 conditions. There are 38 research doctors associated with this hospital, such as Pedro M. Barata, Nakhle Saba, Kendra M. Harris, and Hana Safah.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Human Immunodeficiency Virus Infection
Global LeaderTop PIs
Pedro M. BarataTulane University Health Sciences Center4 years of reported clinical research
Studies Cancer
Studies Renal Cell Carcinoma
20 reported clinical trials
52 drugs studied
Nakhle SabaTulane Cancer Center4 years of reported clinical research
Studies Lymphoma
Studies Mantle Cell Lymphoma
14 reported clinical trials
28 drugs studied
Kendra M. HarrisTulane University Health Sciences Center6 years of reported clinical research
Studies Cancer
Studies Adenocarcinoma
11 reported clinical trials
35 drugs studied
Hana SafahTulane Cancer Center3 years of reported clinical research
Studies Anemia
Studies Tumors
9 reported clinical trials
18 drugs studied
Clinical Trials running at Tulane University School of Medicine
Prostate Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Bladder Cancer
Multiple Myeloma
Coronavirus
Cancer
Plasma Cell Neoplasms
Pneumonia
Squamous Cell Carcinoma
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
PSMA-Based PET Imaging
for Prostate Cancer
Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. Objective: To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Also, to test if this approach is better or worse than the usual approach for prostate cancer. Eligibility: Men ages 18 and older with prostate cancer that appears to be contained within the prostate but is at risk of having spread Design: Participants will be screened with: * Medical history * Blood tests * CT and MRI scans: Participants will lie in a machine. The machine will take pictures of the body. * Bone scan Participants will have a radiotracer injected into a vein. They will have a PET/CT scan of their whole body 60 90 minutes later. During the scan, they will lie on their back and stay still. Within 60 days after the scan, participants will have surgery. This will remove the prostate gland and lymph nodes around it. Some tissue will be used for genetic testing. If the PET/CT scan suggests the cancer has spread, participants may need to have another biopsy within 60 days after the scan. After surgery, participants will have follow-up visits for 5 years. They will have 5 visits the first year and 2 the second. Then they will have visits once a year. If participants cancer returns, they will have repeat PET/CT scans.
Recruiting1 award Phase 29 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Tulane University School of Medicine?
Tulane University School of Medicine is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Cancer, Human Immunodeficiency Virus Infection, Leukemia, Prostate Cancer, Fibrosis and other specialties. Tulane University School of Medicine is involved with conducting 284 clinical trials across 916 conditions. There are 38 research doctors associated with this hospital, such as Pedro M. Barata, Nakhle Saba, Kendra M. Harris, and Hana Safah.